Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017097697) METHOD USING A RET FUSION GENE AS A BIOMARKER TO SELECT NON-SMALL CELL LUNG CANCER (NSCLC) AND THYROID CANCER PATIENTS FOR A CANCER TREATMENT
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/097697 International Application No.: PCT/EP2016/079728
Publication Date: 15.06.2017 International Filing Date: 05.12.2016
IPC:
C12Q 1/68 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173 55216 Ingelheim Am Rhein, DE
Inventors:
HAYASHI, Hidetoshi; JP
NAKAGAWA, Kazuhiko; JP
NISHIO, Kazuto; JP
OKAMOTO, Kunio; JP
SAKAI, Kazuko; JP
SHIMIZU, Toshio; JP
TAKEDA, Masayuki; JP
TANAKA, Kaoru; JP
Agent:
SIMON, Elke; DE
ROTHERMEL, Reinfried; DE
Priority Data:
15198473.908.12.2015EP
Title (DE) METHOD USING A RET FUSION GENE AS A BIOMARKER TO SELECT NON-SMALL CELL LUNG CANCER (NSCLC) AND THYROID CANCER PATIENTS FOR A CANCER TREATMENT
(EN) METHOD USING A RET FUSION GENE AS A BIOMARKER TO SELECT NON-SMALL CELL LUNG CANCER (NSCLC) AND THYROID CANCER PATIENTS FOR A CANCER TREATMENT
(FR) PROCÉDÉ UTILISANT UN GÈNE DE FUSION RET COMME BIOMARQUEUR POUR SÉLECTIONNER DES PATIENTS ATTEINTS D'UN CANCER BRONCHIQUE NON À PETITES CELLULES (NSCLC) ET D'UN CANCER DE LA THYROÏDE POUR UN TRAITEMENT ANTICANCÉREUX
Abstract:
(DE) The present invention relates to a RET fusion gene such as a CCDC6-RET fusion gene as a biomarker to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6- methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments. The present invention also relates to specific uses of said specific compound in the treatment of cancers.
(EN) The present invention relates to a RET fusion gene such as a CCDC6-RET fusion gene as a biomarker to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments. The present invention also relates to specific uses of said specific compound in the treatment of cancers.
(FR) La présente invention concerne un gène de fusion RET tel qu'un gène de fusion CCDC6-RET comme biomarqueur pour surveiller l'activité du composé 3-Z-[l- (4-(N-((4-méthyl-pipérazin-1-yl)-méthylcarbonyl)-N-méthyl-amino)-anilino)-1-phényl-méthylène]-6-méthoxycarbonyl-2-indolinone ou d'un sel pharmaceutiquement acceptable de celui-ci, et en particulier sa forme de sel de monoéthanesulfonate, lorsqu'il est utilisé seul ou facultativement en combinaison avec d'autres ingrédients pharmaceutiquement actifs et/ou d'autres traitements. La présente invention concerne également des utilisations spécifiques dudit composé spécifique dans le traitement de cancers.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP3387145US20190002988